Enteric fever, primarily caused by Salmonella Typhi and Paratyphi, remains a significant global health challenge. Despite advancements in medical science, its management continues to be complex due to increasing antimicrobial resistance and varying disease presentations. This article explores modern strategies in managing enteric fever.
Antimicrobial therapy remains the cornerstone of enteric fever management. The emergence of multi-drug resistant (MDR) and extensively drug-resistant (XDR) strains necessitates the use of newer antimicrobials. Third-generation cephalosporins, such as ceftriaxone, are now the first-line treatment in many regions. Azithromycin is another potent alternative, especially in pediatric patients and pregnant women.
Preventive measures, such as vaccination, play a crucial role in controlling enteric fever. Ty21a and Vi polysaccharide vaccines have been widely used, but they offer limited protection and require multiple doses. The newer conjugate vaccine (Typbar-TCV®) provides longer-lasting immunity and is effective in children under two years, a high-risk group previously unprotected.
Early diagnosis is key to managing enteric fever effectively. Traditional culture methods, though gold-standard, are time-consuming and have low sensitivity. Modern diagnostic techniques, such as PCR and antigen-detection tests, offer rapid and accurate diagnosis, enabling timely intervention.
Public health strategies, including improved sanitation, safe drinking water, and food safety measures, are integral to managing enteric fever. These interventions, coupled with disease surveillance and antimicrobial stewardship programs, can mitigate the spread of resistant strains and reduce disease burden.
In conclusion, the effective management of enteric fever requires a multifaceted approach. It involves not only the use of advanced antimicrobials and vaccines but also the implementation of robust diagnostic methods and public health interventions. As the disease landscape evolves, ongoing research and collaboration are critical to developing innovative strategies to tackle this persistent global health issue.
1.
For MDS-Related Anemia, Telomerase Inhibitor Approved.
2.
Efficacy and safety of intravenous chemotherapy in children with intraocular retinoblastoma
3.
Admissions, medical schools, costs, and eligibility requirements information for FNB Onco-Anesthesia.
4.
Treating Depression: Crucial for Recovery From Fibromyalgia
5.
In postmenopausal women with hormone receptor-positive tumors, obesity increases the risk of breast cancer recurrence.
1.
Empowering Oncology with Data: Cloud Security, Real-World Evidence, and Clinical Insights
2.
Immune Regulation of Blood Cell Development
3.
Exploring the Effects of Radiation Therapy on Cystitis: A Journey to Better Health
4.
Transformative Frameworks in Oncology for Better Care
5.
Liposomal Doxorubicin and Mitomycin in Modern Cancer Treatment
1.
International Conference on Oncology, Cancer Prevention and Public Health
2.
International Conference on Cancer Nursing and Rehabilitation Strategies
3.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
4.
International Conference on Innovations in Critical Care for Oncology and Cardiology
5.
International Symposium on Oncology, Cardiology and Critical Care Innovations
1.
Targeting Oncologic Drivers: A New Approach to Lung Cancer Treatment
2.
Newer Immunotherapies for Myeloma- A Comprehensive Overview
3.
Understanding the causes of anemia in adults beyond nutritional deficiencies
4.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part III
5.
Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation